Posts tagged Neil Maruoka


Oncolytics Biotech Inc. (ONC) Stock Is Significantly De-Risked After End-of-Phase II Meeting with FDA, Cheers Canaccord

Analyst lifts price target on Oncolytics with new clarity from the FDA on Reolysin’s path forward to approval.

Is Valeant Pharmaceuticals Intl Inc (VRX) on the Road to Recovery?

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) posted first quarter financial results yesterday for the year that …

Valeant Pharmaceuticals Intl Inc Takes First Steps To Address Leverage: Canaccord

Canaccord analyst Neil Maruoka came out today with a few thoughts on Valeant Pharmaceuticals Intl Inc …

Canaccord Weighs in on Valeant Pharmaceuticals Intl Inc (VRX) Amid Regime Turnover of High-Level Executives

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares were falling 5% yesterday after the reveal that three …

Beaten Biotech Stock in Spotlight: Valeant Pharmaceuticals Intl Inc (VRX)

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares stumbled over 10% in the past two days, after the …

Canaccord Lowers Price Target on AEterna Zentaris Inc (AEZS); Eyes Peeled to Clinical Drivers

AEterna Zentaris (NASDAQ:AEZS) delivered a financial third-quarter report on Tuesday, November 8th that “modestly” underperformed …

Canaccord Sees Valeant Pharmaceuticals Intl Inc (VRX) as Challenged for Growth

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) posted a third-quarter print yesterday that was decent in terms …

Canaccord Raises Price Target on Valeant Pharmaceuticals International, Inc. (VRX) on Back of Credit Facility Amendment

Analyst Neil Maruoka of Canaccord raised his price target on Hold-rated Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) …

Show More